SCHEMBL30786109

SCHEMBL30786109

CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(Sc4ccccc4C(=O)NC4CC4)ccc23)nc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.73
FGFR1 P11362 6/20 0.60
PLK4 O00444 4/20 0.60
AURKB Q96GD4 3/20 0.60
FLT1 P17948 3/20 0.60
FLT4 P35916 3/20 0.60
AURKA O14965 2/20 0.60
MAP4K4 O95819 2/20 0.60
PAK4 O96013 2/20 0.60
ABL1 P00519 2/20 0.60
LCK P06239 2/20 0.60
CSF1R P07333 2/20 0.60
RET P07949 2/20 0.60
MET P08581 2/20 0.60
PDGFRB P09619 2/20 0.60
KIT P10721 2/20 0.60
PDGFRA P16234 2/20 0.60
FGFR3 P22607 2/20 0.60
TYK2 P29597 2/20 0.60
AXL P30530 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30786249 0.92 KDR (0.71) KDRFGFR1PLK4AURKBFLT1
SCHEMBL31517044 0.88 KDR (0.69) KDRFGFR1PLK4AURKBFLT1
SCHEMBL30786222 0.88 KDR (0.68) KDRFGFR1PLK4AURKBFLT1
SCHEMBL31576734 0.86 KDR (0.71) KDRFGFR1PLK4AURKBFLT1
SCHEMBL31517055 0.85 KDR (0.69) KDRFGFR1PLK4AURKBFLT1
SCHEMBL5254878 0.84 KDR (1.00) KDRFGFR1PLK4AURKBFLT1
SCHEMBL31517038 0.84 KDR (0.59) KDRFGFR1PLK4AURKBFLT1
SCHEMBL31576771 0.84 KDR (0.67) KDRFGFR1PLK4AURKBFLT1
SCHEMBL30786143 0.84 KDR (0.59) KDRFGFR1PLK4AURKBFLT1
SCHEMBL31475191 0.83 KDR (0.70) KDRFGFR1PLK4AURKBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 KDR 1/4885FGFR1 70/4885PLK4 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.